At the end of this month, on Tuesday, September 29, at 8:00-9:30 p.m. Eastern time (to be precise), there will be a second webinar in the series on the role of active surveillance in the management of favorable-risk forms of localized prostate cancer, coordinated by our good friend Howard Wolinsky and others. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, genetics, genomics, Helfand, surveillance, webinar | 3 Comments »
A newly published paper on the development of prostate cancer in patients of ≤ 55 years of age claims to have shown that
Using a newly-developed computer model, it is now possible to predict the course of the disease in individual patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genomics, medicine, modeling, personalized, prognosis | 2 Comments »
For those who are interested in this evolving topic, we recommend listening to Dr. Charles Ryan’s 16-minute-long discussion with Heather Cheng, MD, PhD, entitled “Genetic evaluation and counseling in prostate cancer treatment”. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, Management, PARP, risk | 3 Comments »
Newly published research in Nature Genetics has reported the identification of yet another 63 new variants in the human genome that increase risk for a diagnosis of prostate cancer in males. This takes the total number of such variants identified to date to something approaching 175. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, genetics, genomics, risk | 3 Comments »
According to reports from the Associated Press and others, some time late last Thursday the US Food & Drug Administration (FDA) appears to have approved the use of the FoundationOne CDx genetic/genomic test for patients with “advanced or widely spread cancers.” A media release from Foundation Medicine is also available on line. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: CDx, FoundationOne, genetics, genomics, test | 6 Comments »
According to a study just published in Cancer Research, a completely new technique referred to as “single cell genomics” may be able to improve the accuracy of diagnosis of prostate cancer based on biopsy tissue. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: cell, dagnosis, genomics, Gleason, grade, prognosis, score, single | 2 Comments »
Our friends at UroToday have just published a perfectly lovely lecture on this topic given by Prof. Lenny Gomella at the recent annual meeting of the Large Urology Group Practice Association (LUGPA). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, prognosis, screening, Treatment | 7 Comments »
Dr. Zachary Klaassen and UroToday have provided us with four more interesting summaries of presentations by faculty at the European Association for Urology (EAU)’s meeting in Vienna last weekend. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: biomarkers, care, focal, functional, genomics, imaging, molecular, patient-centered, therapy | 4 Comments »
A new analysis of a large data set compiled by Kaiser Permanente suggests that combining PSA data with genetic risk data may offer a much more effective way to assess risk for clinically significant prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: genomics, gentics, Management, PSA, risk, strategy | 8 Comments »
A media release issued yesterday by Genomic Health, Inc., has suggested that the multi-gene Oncotype DX® Genomic Prostate Score™ is a strong predictor of risk for the development of metastasis and prostate cancer death in patients with early-stage prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biopsy, genetics, genomics, Oncotype, outcome, prognosis, risk | 5 Comments »
So our friends at UroToday have started providing reports on the key presentations that are being given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. Here are links to some interesting reports … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, imaging, quality of life, risk, screening, testing | 1 Comment »
Earlier this month The “New” Prostate Cancer InfoLink stated that the new liquid biopsy test being touted by Pathways Genomics was of no proven value in the diagnosis of prostate cancer and that we expected the U.S. Food and Drug Administration (FDA) would have some comments on the promotion of this test. We were correct. … READ MORE …
Filed under: Diagnosis | Tagged: biopsy, CancerIntercept, genomics, liquid, pathway | Leave a comment »
If you are still under the illusion that, simply by identifying the precise structure of the deoxyribonucleic acid (DNA) of patients’ cancer cells, we will be able to develop and target drugs that can eliminate specific cancers (or indeed other disorders) in specific individuals, an article by Sharon Begley on the Reuters.com web site should help to disabuse you. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: genetics, genomics, personalized, targeted, therapy | 4 Comments »
Over the past few years we have seen a great deal of discussion of this or that new gene or single nucleotide polymorphism (SNP) or other set of genomic data and the potential of such information to improve the diagnosis or the prognosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, prognosis, risk, Treatment | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 